TAIPEI, Taiwan – Taiwan startup Sinew Pharma Inc. is developing what it hopes will be a first-in-class drug to treat nonalcoholic steatohepatitis (NASH). With an investigational new drug (IND) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results